Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: brb who wrote (205)	9/8/1999 10:54:00 AM
From: brb	Respond to of 377

Just found this: Vasogen Inc - NP says Vasogen may begin clinical testing, shares skyrocket Vasogen Inc VAS Shares issued 33,561,122 1999-09-07 close $3.1 Wednesday Sep 8 1999 The National Post reports in its Wednesday edition that shares in Vasogen Inc. rocketed 31.9 per cent yesterday on the possibility that the biotechnology company could begin clinical testing this month for its measures to prevent the organ damage that may occur as a result of surgery. Douglas Janzen, an analyst at Loewen Ondaatje McCutcheon, said the studies should begin by the end of the month and would be carried out at Baylor College of Medicine in Texas, one of the premier cardiovascular research centres in the United Sates. Vasogen confirmed that it is awaiting approval from the U.S. Food and Drug Administration to go ahead with trials at Baylor. Vasogen continues to test its products in the United Kingdom, but "investors like to see trials happen in the U.S." said another analyst. The excitement about possible trials pushed the shares up as high as $3.15 in the course of the day yesterday. The company's stock began trading on the Toronto Stock Exchange on July 22. Mr. Janzen said the listing and the recent inflow of money into the biotechnology sector in general have given Vasogen more visibility.